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Priorities for the Commissioning of Services for 
Drug Users
When commissioning community based services to reduce
the harms associated with problem drug use, in line with
the aims of the national drug strategies 2,3,4,5,6, primary care
bodies* and Drug Action Teams or local partnerships should
give priority to preventing spread of infections among IDUs
and reducing the harm these infections cause through:
1. Continuing the development of high-quality needle-
exchange (NEX) services for those unable to stop
injecting, by:
a. ensuring sufficient distribution of injecting 
equipment to prevent the sharing of needles 
and syringes; 
b. providing injecting-related equipment other than 
needles and syringes as appropriate;  
c. ensuring an appropriate range of NEX services are 
provided, including provision by drug services, 
retail pharmacies, and mobile or outreach services.  
Trained drug workers and nurses should staff NEX services.
2. Ensuring NEX, and other services working with IDUs,
provide: 
a. information and practical advice on safer injecting
practices, avoiding injecting site infections,
prevention of blood-borne virus transmission, and on
the safe disposal of used injecting equipment.  
b. onsite hepatitis B vaccination services, with follow-up
strategies for those who have started vaccination
courses in line with national service specifications 7.
c. easy access to health checks, treatment for abscesses,
and diagnostic tests for hepatitis C and HIV. 
3. Developing mechanisms, with local providers, to ensure
that services that aim to prevent or reduce infections
among IDUs, such as NEX, can respond in a timely
fashion to evolving patterns of drug use (such as
increased crack-cocaine use) and risk. 
4. Further improving access to diagnostic testing for
hepatitis C – particularly to those who have ceased
injecting – in line with strategies such as the ‘Hepatitis C
Action Plan for England’ 8 and the proposed Hepatitis C
Action Plan for Scotland. 
5. Developing procedures for offering tetanus vaccine
and boosters to those IDUs who may need them 
and offering hepatitis A vaccination where this 
is appropriate 9.
6. Promoting a range of easily accessible drug treatment
and support services that encourage drug users to
reduce and cease injecting, and reduce or stop their
drug use.
Key points
1. The prevalence of HIV infection among injecting drug
users (IDUs), in England & Wales at least, has probably
increased in recent years. Overall HIV infection among
IDUs in the UK remains, when compared to other
countries, relatively rare with around one in every 65
injectors infected. The prevalence of HIV among IDUs
has remained substantially higher in London than the
rest of the country with around one in 25 IDUs having
HIV in the capital. 
2. Overall more than two in five IDUs in the UK have been
infected with hepatitis C. In England and Wales hepatitis
C transmission among IDUs is high with one in six of
those who had started to inject since the beginning of
2002 having become infected. In Glasgow, transmission
was higher with one in two IDUs, who had been
injecting for less than two years in 2004, having been
infected with hepatitis C.  
3. Uptake of testing for hepatitis C among IDUs in contact
with drug services has increased in recent years. It is
estimated, however that around half of those IDUs with
hepatitis C in contact with these services still remain
unaware of their infection. There will also be substantial
numbers of current and former IDUs who are not in
contact with services that will be unaware that they
have hepatitis C.
4. Those who report injecting crack-cocaine have higher
prevalences of HIV and hepatitis C infection.
Whilst crack-cocaine use is associated with increased
injecting risk behaviours, the underlying factors for the
higher levels of blood borne virus infection are not as
yet clear, but it is a cause for concern as crack-cocaine
use has become more widespread.
5. The continuing occurrence of wound botulism cases
indicates that environmental contamination of heroin
with bacterial spores remains a problem. Whilst there
are continuing problems with injecting site infections
associated with methicillin resistant Staphylococcus
aureus and severe group A streptococcal infection.
6. Transmission of both hepatitis A and B continues
among IDUs even though there are effective vaccines.
The proportion of IDUs reporting uptake of the hepatitis
B vaccine has increased markedly in recent years, with
the prison vaccination programmes being a major
factor in this increase.
7. Needle and syringe sharing increased in the late 1990s,
and since then has been stable with around one in
three IDUs reporting this activity in the last month.
The sharing of other injecting equipment is more
common, whilst few IDUs swab injecting sites prior 
to injecting.
* Primary Care Trust in England, Local Health Care Co-operatives and NHS Boards in Scotland, 
Local Health Boards in Wales, and Health and Social Services Boards supported by Local Health 
and Social Care Groups in Northern Ireland.4 Shooting Up 
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Priorities for Public Health Surveillance Development
and Research
In commissioning developments to public health
surveillance and research studies priority should be given to:
1. Improving the quality and consistency of the
surveillance of viral hepatitis, through the more
complete and consistent reporting of laboratory
diagnoses, and in particular, improved completeness of
the risk factor information.  
2. There is a need for research to examine the wider
extent of bacterial infections among IDUs as current
data on bacterial infections is focused on the more
severe cases.  
3. The pilot of the enhancement to the UAPMP survey of
IDUs has provided useful additional data and the
continuation of this enhancement needs to be
considered. Establishing a comparable unlinked
anonymous survey programme in Scotland is essential
to monitor the impact of interventions on the spread of
blood-borne viruses, particularly hepatitis C, among
IDUs.
4. NEX services are a key service for preventing infections
among IDUs, however it is currently not possible to
assess the extent of provision. The ongoing national
audits of NEX services, which are mapping current
provision and service levels, should provide important
insights. Needle exchange monitoring systems are
however needed to provide ongoing information.  
The National Treatment Agency for Substance Misuse is
committed to initiating a national monitoring system of
throughput of injecting equipment in England in
2006/07.  
5. The recent increase in infections among IDUs suggests 
a need to re-examine the nature and range of services
provided to IDUs. Research projects to develop, pilot
and evaluate novel and improved service models, 
which aim to encourage and support hygienic 
injection practice, are needed. Research is also 
needed to examine the impact of crack-cocaine
injecting on infections among IDUs and into appropriate 
services responses.
Introduction
1. Injecting drug users (IDUs) are vulnerable to a diverse
range of both bacterial and viral infections, including
HIV, hepatitis C, and wound botulism. These can result
in high levels of morbidity and mortality. The public
health surveillance of infectious diseases, and the
associated risk and protective behaviours, among this
group are important.  
2. The extent of injecting drug use in the United Kingdom
(UK) is uncertain. Two studies funded by the Scottish
Executive have provided estimates of the prevalence of
problem drug misuse in Scotland: these indicated that
the number of current injectors in Scotland had
reduced from around 25,000 in 200010,11, to 19,000 in
200312 (representing 0.9% and 0.7% of those aged 15
to 54 years, respectively). In England there are only
estimates for selected cities (for example, 34,000 (1.2%)
injectors aged 15 to 44 years in London13), but these
are believed to be high prevalence areas. There are no
recent published studies for Wales or Northern Ireland.
It is likely, however, that the overall prevalence has
increased14. The National Survey of Sexual Attitudes and
Lifestyle reported that for those aged 15 to 44 years
1.3% in 2000 had “ever injected” compared to 0.8% in
199015,16. The number of opiate overdose deaths
increased five-fold from 1990 to 2000  and a pilot back-
calculation model suggested that in 2000 17 there may
have been between 100,000 and 150,000 current IDUs
(0.5% to 0.7% of those aged 15 to 44)18.
3. In 1998 the national drug strategy was launched -
Tackling Drugs to Build a Better Britain19- and this was
updated in 20022. Scotland6, Wales4 and Northern
Ireland5 have adopted country-specific strategies within
the national one. There have also been a number of
initiatives, such as the establishment of the National
Treatment Agency for Substance Misuse and the Models
of Care20 initiative in England, to support the
development of services to meet the strategies aims. 
4. This report presents available data on the extent and
trends over time of infections among IDUs in the UK in
2004. It includes data on the more severe bacterial
infections affecting IDUs, on relevant markers of HIV and
viral hepatitis prevalence and incidence, and on
associated risk and protective behaviours. 
Risk and Protective Behaviours
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*Those who last injected drugs in the four weeks prior to participating in the survey.
#Sharing of needle or syringes in the previous four weeks.
Data source:Unlinked Anonymous Prevalence Monitoring Programme survey of injectors in contact 
with drug agencies.
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Figure 1
Trends in equipment sharing #,past hepatitis B & C infection,and HIV infection
among current Injecting Drug Users* in England &Wales: 1992 to 2004
*
5. Infections among IDUs are associated with a wide range
of behavioural and environmental factors, such as, the
sharing of injecting equipment and homelessness.
Preventive interventions are designed to target these
factors and reduce the harms associated with drug use.
England, Wales & Northern Ireland
6. In 2004 the proportion of current IDUs (those who had
injected in the four weeks prior to taking part in the
survey) sharing needles and syringes (direct sharing)
remained high, with 28% (435 of 1,547) of participants
in the Unlinked Anonymous Prevalence Monitoring
Programme’s (UAPMP) survey of IDUs in contact with
drug agencies reporting this (figure 1). 
The proportion reporting direct sharing varied by region
and country (figure 2). When data for 2003 and 2004
were combined the highest level was found in Northern
Ireland, where 36% (30 of 84) reported direct sharing,
whilst in Wales 22% (14 of 63) reported this. 
7. Initial results from the UAPMP enhancement pilot (which
recruited current IDUs at locations in the South West, 
North West and North East regions of England during
2003/04) found that 34% (213 of 628) reported direct
sharing. This survey also asked participants about the
number of times they had used their last needle and
47% had used it more than once (441 of 939). 
Whilst almost three quarters (72%, 680 of 946)
reported ever having tried to clean needles and syringes
before reuse.
8. The sharing of items such as filters, spoons and flushing
water by participants in the UAPMP agency survey
continued at high levels in England with 50% (719 of
1,442) of current injectors reporting this in 2004. 
High levels were also found in Wales 44% (27 of 62) 
and in Northern Ireland 52% (44 of 84) (2003 and
2004 data combined). The most commonly shared
items in England, Wales and Northern Ireland were
mixing containers such as spoons (43%, 701 of 1,627). 
9. The UAPMP enhancement pilot asked about injection
hygiene and found that only a third of IDUs always
swabbed injection sites (33%, 313 of 948). In the last
year four fifths (58%, 555 of 952) of the participants 
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* Vaccination uptake data should be interpreted with caution as they are based on self-reports.
Figure 2
Geographic variations in the prevalences of hepatitis C and B, hepatitis B vaccine uptake # and equipment
sharing+ among current & former Injecting Drug Users in England, Wales & Northern Ireland
(2003 and 2004 data combined)
#Self reports, those receiving one or more vaccine doses.
+Sharing of needles or syringes in the previous four weeks.
Data source: Unlinked Anonymous Prevalence Monitoring Programme survey of injectors in contact with drug agencies.
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reported having a possible symptom of an injection site
infection or reaction (redness, swelling or tenderness),
and a third (36%, 344 of 952) reported an abscess,
sore, or open wound at an injection site. Almost half of
those reporting these had sought medical attention
(53%, 341 of 645).
10. The UAPMP enhancement pilot asked participants about
the different drugs they had injected. Those that
reported injecting crack-cocaine (40%, 382 of 952),
either alone or with other drugs, reported higher levels  
of risk behaviours. Those injecting crack-cocaine were 
more likely than those who had not to report direct
sharing in the last month (42% (102 of 243) compared
with 29% (111 of 385)), and to have used their last
needle five or more times (15% (57 of 377) compared
with 8% (47 of 562)). They were also more likely to
have had an abscess, sore, or open wound at an
injection site in the past year (45% (172 of 382)
compared with 30% (172 of 570) of those not 
injecting crack-cocaine). Crack-cocaine injectors were
also more likely to have been homeless in the last year  
(67% (310 of 381) compared with 53% (417 of 569) for
those not injecting crack-cocaine). 
11. In 2004, 88% (2,326 of 2,644) of IDUs participating in
the UAPMP agency survey reported that they had, at
some time in their injecting career, accessed a needle
exchange (NEX) service. In 2004 of those who had first
injected in the previous three years, 85% (291 of 341)
had accessed a NEX (table 1).  
12. The numbers of IDUs participating in the UAPMP agency
survey self-reporting* that they had been vaccinated
against hepatitis B has more than doubled from 25%
(784 of 3,114) in 1998 to 56% (1,468 of 2,631) in 2004
(table 1). Of those who had reported vaccination, just
over half self-reported receiving three or more doses of
the vaccine (55%, 776 of 1,402). Self-reported
vaccination uptake varied by region and country
(combining 2003 and 2004 data, figure 2), and in
Wales was 46% (44 of 96) and in Northern Ireland 49%
(74 of 151). In 2004 of those who had first injected in
the previous three years, 51% (173 of 341) reported
uptake of the vaccine (figure 3). 
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† Provisional data.
‡ Health-board data for financial year 2004/2005 were not available at the time of publication. 
Hepatitis B
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Figure 3
Trends in hepatitis B vaccine uptake#,past hepatitis B & C infection,and HIV infection
among recently initiated Injecting Drug Users* in England &Wales: 1992 to 2004
*Those who started injecting drugs in the three years prior to participating in the survey.
#Self reports, those receiving one or more vaccine doses.
Data source:Unlinked Anonymous Prevalence Monitoring Programme survey of injectors in contact 
with drug agencies.
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13. The UAPMP enhancement pilot asked about sources of
hepatitis B vaccine doses. Of those participants who
received one or more doses of vaccine the most
common reported source was prisons 37% (221 of 598).
Only 14% (84 of 598) reported receiving a dose from a
NEX. 
14. The UAPMP enhancement pilot also found that 20%
(165 of 831) self-reported receiving hepatitis A
vaccination, indicating low uptake.  
Scotland
15. In the financial year 2004/05, drug treatment agency
reports to the Scottish Drug Misuse Database (SDMD)
indicated that 31%† of current IDUs had shared a needle
and syringe in the previous month; this compares with
rates in the range of 33% to 36% during previous years
1998/99 to 2003/04 (table 1). Figure 4 shows the
regional variation in reported direct sharing in the
previous month by current IDUs during the financial year
2003/04‡, ranging from 19% in Dumfries and Galloway
to 46% in Forth Valley.
16. SDMD recorded data on the sharing of injecting
equipment other than needles and syringes for the first
time in the financial year 2001/02. The percentage of 
current IDUs sharing spoons, filters and water in the
previous month was 48%† in 2004/05, 49% in 2003/04,
48% in 2002/03 and 50% in 2001/02.
17. Community-wide surveys of IDUs in Glasgow found a
significant increase in hepatitis B vaccine uptake among
those who had injected for ≤5 years in 2001/02 (52% of
387) compared to 1993, 1994 and January-March 1999
(16% of 432)21. During 2004, a further increase in
vaccine uptake was detected among IDUs surveyed in
Glasgow (65% of 167 individuals who had injected for
≤5 years). 
18. In December 2002, Scotland's Lord Advocate
introduced new guidelines on the number of needles
and syringes dispensed at any one visit to a NEX: a
maximum of 20 sets (previously 5 sets) on the first visit;
a maximum 60 sets (previously 15 sets) on subsequent
visits; and an upper limit of 120 sets (previously 30 sets)
for holiday periods. In a study conducted in Glasgow
during 200422, only 20% of current IDUs were aware of
these increases. Nevertheless, significant reductions in
both frequency of injecting and rates of needle and
syringe sharing among recent initiates to injecting were
observed between 2001/02 and 200422.
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Bacterial infections
Staphylococcus aureus infections
§The MRSA exhibit a distinctive antibiogram (ciprofloxacin susceptible, but fusidic acid and erythromycin
resistant), are lysed by a broad range of bacteriophages, and encode enterotoxins A and H.  
19. IDUs are vulnerable to a range of bacterial infections,
such as wound botulism, ‘gas gangrene’, and
bacteraemias, as a result of non-sterile injecting or
injecting contaminated drugs. In recent years these acute
infections have caused growing public health concern.
Staphylococcus aureus Infections
20. Staphylococcus aureus is a common pathogen among
IDUs, causing infections that vary in severity from minor
skin and soft tissue infections through to life-threatening
invasive disease such as bacteraemia and endocarditis.
Typically, isolates from these individuals are methicillin
sensitive S. aureus (MSSA), but the lack of systematic
studies and active surveillance means that little is known
about the extent or epidemiology of MSSA among the
IDU population in the UK. More recently, methicillin
resistant S. aureus (MRSA) has been reported in IDUs in
Switzerland and the United States of America. 
21. A number of centres in England and Wales have
reported encountering MRSA as a cause of injecting
drug use related sepsis in the community 23,24.
The Health Protection Agency’s (HPA) Staphylococcus
Reference Laboratory (SRL) has received sporadic and
small clusters of isolates. Between April 2003 and March
2005 a total of 37 cases of injecting drug use related 
sepsis due to MRSA have been identified from 
geographically distinct areas throughout England and
Wales. There were 25 males and 12 females; 20
presented with injection site abscesses or skin infection,
11 with bacteraemia, and two with endocarditis (clinical
data were not available for four). Cases are continuing
to be reported.
22. Detailed analysis of the MRSA isolates has revealed that
they represent a community MRSA clone that displays a
number of characteristic markers §. This clone is distinct
from prevalent healthcare-associated epidemic MRSA in
the UK (EMRSA-15 and EMRSA-16). In accordance with
International nomenclature, this clone is known as ST1-
MRSA-IV and is one of the most common community-
associated MRSA strains currently seen in England and
Wales25 and has been reported previously in Australia 26.
It is important to note that this strain does not encode
the Panton Valentine Leucocidin (PVL) toxin that has
been associated with serious disease. Nevertheless, as
with PVL-positive community MRSA strains, this clone
can cause skin and soft tissue infection.
23. The mainly sporadic occurrence of the MRSA strains,
with their geographical and temporal distribution, does
not suggest a drug contamination problem.
Nevertheless, more detailed epidemiological
information would be required to elucidate possible
links. Continued surveillance will further our
understanding of the pathogenicity and epidemiology
of this unusual clone. 
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Argyll & Clyde (N=332)
 Tayside (N=93)
Lothian (N=502)
Greater Glasgow (N=877)
 Fife (N=360)
Highland (N=59)
Grampion (N=441)
 Lanarkshire (N=80)
Forth Valley (N=108)
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41%
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32%
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22%
19%
40% 60% 80% 100%
Figure 4
Prevelance of needles/syringes sharing in the previous month among 3,160 injecting drug users in Scotland
by health-board area,2003/2004 financial year +
Data source: Scottish Drugs Misuse Database, ISD
Shared needles/syringes in the previous month 
All Scotland 
34% of 3,160 IDUs
+ Health-board data for financial year 
2004/2005 were not available at the 
time of publication. Data are presented for 
individuals who had (i) attended a drug 
treatment service (for the first time ever 
or the first time in at least six months), 
(ii) reported having injected in the previous 
month, and (iii) provided information on 
needles/syringes sharing. 
Data for Borders (N=18), Orkney (N=0) and 
Shetland (N=13) involved few cases 
and are not presented.
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** Serotypes M1, R28, M11 and M12 predominated during the years 1995 to 1998 with the emergence
of ‘higher types’ during recent years; M78, M82, M83, M87, M89.
Referrals from
IDUs
Referrals from
Non-IDUs
Data source: Group A streptococci sterile site isolate referrals to the HPA Streptococcus & Diphtheria 
Reference Unit.
*Provisional data.
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Figure 5
Invasive isolates of group A streptococci from Injecting Drug User (IDU) and non-IDU 
patients: United Kingdom 1995 to 2004
D
27. The reasons for the changes in reports of GAS
bacteraemia amongst IDUs are not fully understood.
The increases up to 2003 may be due in part to
increased awareness and microbiological investigations
following the severe unexplained illness amongst IDUs 
in 2000 probably due to Clostridium novyi 28,29.
However, the trends seen by CfI pre-date that outbreak.
Furthermore, findings from a cluster in London where
risk factor information and routine sampling had been
undertaken in a consistent fashion since 1970 argue
against increased ascertainment as the sole explanation
for the increase30. The subsequent decrease in 2004,
particularly in specific areas in the north of England
where previous increases have been reported31, may 
be attributable to the success of targeted healthcare
interventions, but this has yet to be confirmed.
28. Data from strep-EURO will help place the current trends
observed in the UK in European context and describe
any other common risk factors in these cases. Early
results from the UK are pointing to injecting drug use
being the most important risk factor for severe group A
streptococcal infections32. Further epidemiological
investigation should be undertaken to gain specific 
risk information of relevance to IDUs, particularly
injecting practices. 
Group A Streptococcal Infections
24. Group A streptococci (GAS) can cause skin sepsis,
bacteraemia and necrotic infections among IDUs
through infection of injecting sites.
25. Although routine laboratory reports of invasive GAS
infections to Centre for Infections (CfI) rarely contain
information on risk factors, isolate referrals to the
HPA’s Respiratory and Systemic Infection Laboratory
(RSIL) do contain such information. Monitoring of
these has identified a rise in referrals from IDUs,
from less than ten per annum in the early to mid-
1990s to 81 in the first nine months of 2002 27.
A total of 281 invasive GAS reports in IDUs were
received in 2003 and 143 in 2004 (figure 5). 
26. Most cases presented with skin sepsis, bacteraemia
and evidence of tissue damage at the injection site,
which ranged from extensive oedema to necrosis.
The majority were sporadic cases but several
clusters were also identified. Serotyping data has
revealed a diverse range of types**. 
The geographical and temporal dissemination along
with the serological typing data do not suggest a
drug contamination problem.
Group A Streptococcal infections
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cases between 1995 and 2000 33. Only two of the 175
tetanus cases identified in England and Wales through
enhanced surveillance between 1984 and 2000 were
known to be IDUs34. An outbreak of tetanus among in
IDUs occurred in 2003 and continued into 2004 with
23 cases reported in England and Wales 35,36,37 the
majority had generalised tetanus and two cases died.
There were also three cases in IDUs, one of whom died,
notified in Scotland during 2003 and 2004 37.
Most cases reported subcutaneous injection of heroin
(‘skin popping’), and the majority were in women with
the male cases being older. Many cases were 
un-immunised or partially immunised and most had
tetanus antibody levels below the protective threshold.
The widespread distribution of the cases within the UK
suggest that the outbreak may have been due heroin
being contaminated with tetanus spores relatively high
in the supply chain. This has led to vaccination guidance
for IDUs being updated to ensure that their tetanus
immunisation status is actively checked 9.
Other Clostridial infections
35. In addition to botulism and tetanus there are other
serious Clostridial infections that may be acquired
through injecting contaminated drugs. During 2000
there was an outbreak of serious illness and death
among IDUs, due to Clostridium novyi 28,38.
Laboratory work has shown that C.novyi spores can
easily survive the “cooking-up” process prior to heroin
injection39. There have been reports of Clostridium
histolyticum infection among IDUs40, some of whom
also had tetanus. Molecular typing has revealed that
isolates from cases across the UK in 2003 were
indistinguishable indicating a common source 
of contamination 41.
Clostridial infections  
29. Clostridia are a group of spore forming bacteria that are
widely found in the environment. The spores produced
by these bacteria may end up in drugs, such as heroin,
through environmental contamination. They may cause
wound infections among IDUs, particularly if they enter
an intramuscular or subcutaneous injection site, and can
then produce toxins causing illness such tetanus or ‘gas
gangrene’ with potentially severe or fatal outcomes.
Wound botulism 
30. Botulism is an illness caused by botulinum toxin, a
poison produced by the bacterium Clostridium
botulinum. Symptoms of botulism include blurred vision
and difficulty in swallowing and speaking, and it can
also result in paralysis and death. However there is an
effective antitoxin. When it infects wounds, including
injecting sites, it causes wound botulism.  
31. Prior to 2000 no cases of wound botulism had been
reported among IDUs in the UK, by the end of 2004 a
total of 89 cases have been reported in the UK and Eire.
Overall, 70 (79%) of the cases occurred in England, 13
in Scotland, 2 in Wales and the remaining 4 in Eire. No
cases were reported from Northern Ireland. Overall, 40
(45%) of the 89 cases were laboratory confirmed by the
detection of botulinum neurotoxin in serum (33 cases),
or by the isolation of C.botulinum from wounds (25
cases). Based on the neurotoxin detected or the
C.botulinum isolated from the 40 laboratory confirmed
cases, 35 were due to type A, three to type B and two
to types A and B.  
32. During 2004, 41 cases were reported, and 36 of these
were in England. There was some geographical
clustering with cases being concentrated in two regions
of England: Yorkshire and Humber, and London (figure 6).
Tetanus  
33. A toxin produced by Clostridium tetani causes tetanus.
It usually presents with local fixed muscle rigidity and
painful spasms confined to the area close to the site of
injury or injection, however symptoms can range from
mild trismus (‘lockjaw’), neck stiffness and/or abdominal
rigidity to generalised tetanus (a serious condition that
can include respiratory difficulties and severe painful
spasms). Tetanus is a vaccine preventable disease, and
the vaccine is routinely offered in childhood and
adolescence as well as to adults for specific indications9.
Potential sources for tetanus infection in IDUs are
contaminated drugs, injecting equipment and skin.
34. In the UK tetanus had rarely been reported in IDUs, in
contrast to reports from the United States of America 
where IDUs accounted for around one in six of tetanus  
Clostridial infections
Figure 6
Distribution of reported  
wound botulism 
cases among injecting  
drug users in the 
United Kingdom: 2004
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* Provisional, reports are subject to reporting delay.
#
Data on exposure is often incomplete or missing.
^ Includes Northern Ireland from 2002.
~ Unlinked Anonymous Prevalence Monitoring Programme survey of injectors in contact with drug services.
‡ Denotes past or current infection with hepatitis B/C.
Table 1
Summary of indicators of viral hepatitis and HIV transmission among Injecting Drug Users in the United Kingdom
Indicator
Hepatitis C infection
Reported laboratory diagnoses of 
hepatitis C infection
Proportion hepatitis C antibody positive~‡
Prevalence among those having voluntary
confidential HIV tests 
Hepatitis B infection
Reported laboratory diagnoses of hepatitis B
infection
Proportion hepatitis B antibody positive~‡
HIV infection
Reports of new diagnoses of HIV infection
through injecting drug use
Prevalence among those having voluntary
confidential HIV tests 
Proportion HIV antibody positive~
Behaviour
Passing on or receiving used needles or syringes
in the last month – self reports~
Sharing of needles and syringes in past month –
agency reports¶
Sharing of any injecting equipment in past
month – self reports~
Markers of health care utilization
Ever used a needle exchange~
Ever had a voluntary confidential test for 
hepatitis C ~
Hepatitis B vaccine coverage – 
self reported~
Proportion of those unaware that they have
hepatitis C infection – self reported~
Proportion of those unaware that they have 
HIV infection – self reported~
Area
England
Wales
Scotland
Northern Ireland
England, Wales &
Northern Ireland^
Glasgow
England
Wales
Scotland**
Northern Ireland***
England, Wales &
Northern Ireland^
London
Scotland
Rest of UK
UK
Scotland
England, Wales & 
Northern Ireland^
England, Wales &
Northern Ireland^
Scotland
England, Wales &
Northern Ireland^
England, Wales & 
Northern Ireland^
England, Wales & 
Northern Ireland^
England, Wales & 
Northern Ireland^
England, Wales & 
Northern Ireland^
England, Wales & 
Northern Ireland^
Sub-Category
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use
#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use
#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use
#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use
#
Current & former injectors
First injected during the last 3 years
Injectors: all ages
Injectors: age under 25 years
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use
#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use
#
Total number of reports: all exposures
Proportion of all reports, with exposure data,
indicating injecting drug use
#
Total number of reports: all exposures 
Current & former injectors
First injected during the last 3 years
Total number of reports: injecting drug use
Total number of reports: injecting drug use
Total number of reports: injecting drug use
Total number of reports: men who have sex with
men & injecting drug use 
All injectors tested
Current and former injectors
First injected during the last 3 years
Current injectors 
Current injectors aged ≤24 
Current injectors who first injected during the 
last 3 years
Current injectors
Current injectors
Current injectors who first injected during the 
last 3 years
Current & former injectors
First injected during the last 3 years
Current & former injectors
Current & former injectors anti-HCV positive
Current & former injectors anti-HIV positive 
n
%
n
%
n
%
n
%
%
%
%
%
n
%
n
%
n
%
n
%
%
n
n
n
n
%
%
%
%
%
%
%
%
%
%
%
%
%
%
13
62
41
64
42
1990
–
–
–
–
37
45
1
0
–
–
89
91
599
26
19
13
249
22
37
33
21
112
28
61
239
2.8
1.3
0.8
–
–
–
–
–
–
–
–
–
–
–
1991
–
–
–
–
274
32
13
9
–
–
–
–
555
21
17
11
200
25
28
31
7
121
51
71
287
3.2
1.8
0.0
24
35
26
–
–
–
–
–
–
–
–
1992
228
53
13
13
381
57
48
3
–
–
–
–
512
20
19
30
120
18
34
35
16
108
27
52
228
1.9
1.6
0.0
20
27
22
–
–
–
–
–
–
–
–
1993
410
66
25
100
524
85
7
50
–
–
–
–
605
25
24
13
186
9
22
34
13
90
52
61
238
2.9
1.3
0.4
18
25
23
–
–
–
–
–
–
–
–
1994
796
76
43
100
839
88
43
27
–
–
–
–
603
26
30
32
166
10
33
29
10
78
30
59
211
1.5
1.1
0.1
17
25
21
–
–
–
–
–
–
–
–
1995
1,463
80
183
88
1,147
85
63
43
–
–
77
59
584
39
28
55
152
9
30
22
5
101
22
59
216
1.5
1.4
0.2
17
26
22
–
–
–
–
–
–
–
13
1996
2,116
85
411
84
1,256
91
55
53
–
–
80
61
525
41
45
64
184
10
31
22
7
80
32
61
224
1.5
0.6
0.3
18
24
21
28
58
–
–
–
–
–
29
1997
2,652
92
386
97
1,468
92
54
64
–
–
68
43
621
48
31
53
215
11
22
18
3
76
31
63
192
1.4
1.0
0.3
17
25
22
28
55
–
–
–
–
–
38
1998
4,101
90
378
93
2,008
95
65
68
41
12
–
–
806
45
37
71
295
20
18
22
5
59
19
54
161
0.8
0.9
0.4
32
38
31
34
63
–
–
14
25
–
32
1999
5,294
91
429
96
1,961
95
46
78
35
11
712
51
38
54
386
30
24
20
5
55
16
42
135
0.7
0.8
0.1
33
40
31
34
63
–
–
17
29
–
16
¶
Scottish drug misuse database: data are for financial years, for example, 2002 data relates to 2002/03 financial year.
** Scottish data can not distinguish between acute and chronic hepatitis B infection.
*** Northern Ireland data prior to 2003 could not distinguish between acute and chronic hepatitis B infection: in 2004 there were 20 acute cases.
2004
7,843
95
244
100
-
-
85
100
41
20
–
–
–
–
–
–
341
6
60
21
7
50*
11*
57*
133*
0.5
1.4
0.6
28
36
27
34
55
85
67
51
56
49
50
2003
6,341
95
322
100
1,779
93
83
75
42
20
676
38
25
27
342
6
76
22
9
48*
10*
69*
146*
0.6
1.2
0.8
29
37
28
34
55
86
63
42
50
53
31
2002
5,547
97
351
99
2,325
93
75
89
39
15
829
37
55
69
354
10
67
22
7
59
7
48
140
0.5
1.0
0.3
34
43
33
32
60
84
57
35
43
58
21
2001
4,666
96
292
96
1,904
94
65
75
36
18
–
–
554
37
44
39
357
19
37
21
8
53
16
64
151
0.7
1.0
0.4
33
36
28
36
59
86
54
28
37
59
40
2000
4,892
92
341
97
2,175
94
55
82
35
11
704
46
24
35
360
25
42
21
7
52
15
47
147
0.7
0.8
0.0
31
31
24
34
60
84
49
26
35
60
18
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Hepatitis C
Viral Infections
36. IDUs are vulnerable to a range of viral infections through
the use and sharing of contaminated injecting
equipment. Some of these infections, such as hepatitis
C and HIV, cause long-term chronic illnesses that have
asymptomatic phases that can last many years.   
Hepatitis C
37. Hepatitis C is currently the most significant infectious
disease affecting those who inject drugs. Very high
prevalences have been reported among IDUs from
many countries. Up to 80% of those acquiring hepatitis
C develop chronic infection and are at risk of developing
cirrhosis and liver cancer. Uptake of diagnostic testing
for hepatitis C by current and former IDUs is increasingly
important with the development of new and more
effective antiviral therapies. At the Royal College of
Physicians of Edinburgh Consensus Conference on
Hepatitis C, during April 2004, it was recommended
that “a high priority for case finding should be given to
former injecting drug users, especially those over 40,
who are likely to have a stage of disease which would
benefit from treatment”42. Countries within the UK have
developed strategies to respond to hepatitis C 8,43,44
and much of the focus of these is on current and
former IDUs.  
England 
38. Up to the end of 2004 laboratories had reported a total
of 46,349 diagnoses of hepatitis C infections to CfI since
reporting began in 1992. The majority of these
infections will most probably have been acquired
through injecting drug use as over 90% of those
diagnoses with risk factor information gave this as the
route of infection (table 1). The number of laboratory
reports each year has been increasing since the
introduction of diagnostic tests in the early 1990s, from
under 1,000 per annum prior to 1994 to 7,843 in 2004.
This rise most probably reflects the increasing numbers
of those at risk being tested, rather than an increase 
in infection.
39. In 2004, 42% (1,063 of 2,521) of IDUs who took part in
the UAPMP agency survey‡ had antibodies to hepatitis C
(anti-HCV). This prevalence is similar to that in 2003,
43% (1,132 of 2,615). There were marked regional
variations in the prevalence of hepatitis C (figure 2) from
20% (103 of 525) in the North East to 55% (787 of
1,445) in London and 59% (410 of 697) in the North
West (data from 2003 and 2004 combined).
40. Amongst current IDUs (those who had injected in the
four weeks prior to taking part in the survey) the
prevalence had increased from 40% (870 of 2,179) in
1998, the year hepatitis C testing was added to this
survey45, to 45% (695 of 1,531) in 2004.  
41. Initial results from the UAPMP enhancement pilot found
that 54% (512 of 952) of the participating current IDUs
were anti-HCV positive. This is comparable to the
UAPMP agency survey after allowing for the differences
in test sensitivity and recruitment areas. Those who
reported injecting crack-cocaine had a much higher
prevalence than those who did not (67% (255 of 382)
and 45% (257 of 570) respectively).
42. One of the aims in the ‘Hepatitis C Action Plan for
England’ 8 is to increase the proportion aware of their
infection through improved uptake of voluntary
confidential testing. It sets a national standard of good
practice that all those attending specialist drug
treatment services should be offered hepatitis C testing
routinely. Whilst most IDUs who took part in the UAPMP
agency survey reported having accepted the offer of a
test, in 2004 33% of IDUs (774 of 2,351) reported never
having had a voluntary confidential test for hepatitis C,
this compares with 51% (1,532 of 2,998) in 2000.  
Of those who were infected with hepatitis C, 49% (461
of 945) were unaware of their infection, compared to
60% (620 of 1,032) in 2000.
43. One of the  ‘Hepatitis C Action Plan for England’ 8
outcome measures is the prevalence of hepatitis C in
those who began injecting in the last three years; a
measure of recent transmission. In 2004 among those
in this group who participated in the UAPMP agency
survey the prevalence was 20% (66 of 327), which was
similar to that between 2001 and 2003 but almost
twice the prevalence among this group in 2000 (12%,
89 of 767) and earlier years. A recent increase in
transmission is supported by the findings of the cohort
study undertaken in London by Centre for Research on
Drugs and Health Behaviour (CRDHB) in 2001/03. This
study, which followed a group of IDUs with short
injecting careers for one year, estimated the incidence
to be 42% 46. As this incidence rate is similar to the
prevalence it too suggests that transmission may have
recently increased.
‡ Note: Hepatitis C antibody results from the UAPMP agency survey are different from those 
reported previously. This is due to the retrospective application of a more sensitive cut-off point 
to the hepatitis C laboratory test used on the oral fluid samples. 
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Scotland
44. During 2004, it was estimated that approximately
50,000 persons were infected with hepatitis C in
Scotland (representing 1% of the population) 44. Of the
50,000 persons living with hepatitis C, it was estimated
that 37,500 (75%) were chronically infected (including
33,000 individuals who had ever injected drugs) and
that for between 30% and 40% their infection had 
been diagnosed44.
45. Of the 33,000 ever injectors living with chronic hepatitis
C in Scotland during 2004, it was estimated that
22,800, 8,400 and 1,800 had mild, moderate and
severe (cirrhosis) hepatitis C disease, respectively 47.
UK consensus guidelines recommend that antiviral
treatment should be considered for patients who have
at least moderate hepatitis C disease according to
histological appearances48. Assuming the continuation
of current rates of hepatitis C transmission and uptake
of antiviral therapy, it is predicted that in the year 2020,
19,000, 18,000 and 3,000 ever IDUs will have mild,
moderate and severe hepatitis C disease, respectively 47.
46. To the end of 2003‡ , a total of 18,109 persons had
been diagnosed anti-HCV positive in Scotland. In 2003,
1,779 new diagnoses were reported; this compares with
an annual average of 2,075 reports during the period
1998 to 2002 (table 1). Among the 12,166 reports for
which risk information was available, 11,010 (90%) were
known to have ever injected drugs.
47. In Scotland, residual sera from specimens provided by
IDUs, originally tested for HIV, are anonymously tested
for anti-HCV so as to monitor trends in hepatitis C
prevalence among this group49. Table 1 shows that the
prevalence of hepatitis C among IDUs in Glasgow
reduced significantly between 1990 (all IDUs: 89%; IDUs
aged under 25 years: 91%) and 1999/2000 (62%; and
41% respectively), suggesting that there had been a
decrease in the incidence during the 1990s. Since then,
the prevalence of hepatitis C among IDUs in Glasgow
has risen slightly, but not significantly (in 2002/03, all
IDUs: 64%; IDUs aged under 25 years: 43%).
48. In 1999/2000, the prevalence of hepatitis C among 
IDUs who had undergone a voluntary confidential HIV
test throughout Scotland was 44% (946 of 2,141). 
The prevalence of hepatitis C among these 2,141 IDUs
by health-board area ranged from 23% among IDUs 
in Forth Valley to 62% in Greater Glasgow and 53% 
in Tayside10.
49. During 2004, a community-wide survey of 531 current
IDUs in Glasgow found the prevalence of hepatitis C was
as high as 77% 50. Among the 55 IDUs who had
commenced injecting in the previous two years, the
prevalence of hepatitis C was 51%; this prevalence was
higher than that detected among equivalent IDUs
surveyed in 1999 (24% of 126) and 2001 (43% of 120).  
Wales
50. Laboratories in Wales have reported a total of 3,418
diagnoses of hepatitis C infection; including 244
diagnoses in 2004. Over 90% of infections in individuals
with a known risk factor were associated with injecting
drug use.
51. Combining data from the IDUs who took part in the
UAPMP agency survey in 2003 and 2004, 18% (17 of
97) were anti-HCV positive. This was unchanged from
the prevalence in 1998/99 (18%, 59 of 325). 
Of participants in the UAPMP agency survey in 2003/04,
54% (49 of 91) reported not having a voluntary
confidential test for hepatitis C. Four fifths (14 of 17) of
the IDUs with hepatitis C from Wales participating in the
survey were unaware of their infection.
Northern Ireland 
52. Laboratories in Northern Ireland have reported a total of
758 diagnoses of hepatitis C infection. In 2004 there
were 85 new diagnoses the highest yearly total reported
so far.  
53. Combining data from the IDUs who took part in the
UAPMP agency survey in 2003 and 2004, 25% (38 of
153) were anti-HCV positive. Of the participants, 23%
(33 of 145) reported not having a voluntary confidential
test for hepatitis C, and one fifth (7 of 34) of the
participating IDUs with hepatitis C were unaware of their
infection.
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‡ Note: Hepatitis C diagnoses data were not available for Scotland up to the
end of 2004 at the time of publication.
54. Hepatitis B infection is usually acquired in adulthood in
the UK, with sexual activity or injecting drug use being
the most commonly reported routes of infection.
Infection with hepatitis B virus typically causes an 
acute infection, with a small number of those infected
going on to develop chronic disease. Infection with
hepatitis B is however preventable using a safe and
effective vaccine.
55. In England and Wales acute hepatitis B cases are
reported to CfI, in 2004 there was a substantial
deterioration in the quality of hepatitis B reporting and
data for 2004 is unavailable§§. However, in 2003
injecting drug use was the main risk group associated
with hepatitis B infection, accounting for 34% of
individuals with a known risk factor in England, and 
27% in Wales.  
56. In Scotland and Northern Ireland, reported hepatitis B
diagnoses encompass both acute and chronic hepatitis
B infections. In Scotland, there were 341 reports in
2004; this annual total is similar to those for the period
2000 to 2003. The proportion of reports that indicated
that cases had injected drugs declined from 30% in
1999 – the year in which an outbreak occurred among
the IDU population in Aberdeen – to 6% in 2004 (table
1).  In Northern Ireland the total number of reports
(acute and chronic) of hepatitis B infection prior to
2002 had fluctuated at around 30 reports each year.
There were 67 reports in 2002, 76 in 2003, and in
2004 there were 60 reports. Some of these infections
will have been related to injecting drug use. 
57. In 2004, 21% (572 of 2,686) of IDUs who took part in
the UAPMP agency survey in England, Wales & Northern
Ireland had antibody to hepatitis B core antigen (anti-
HBc, a marker of previous or current hepatitis B
infection); this was similar to the level observed since
1995 (table 1). The prevalence varied by region and
country (combining 2003 and 2004 data): in England,
the highest prevalence was found in the North West
(29%, 205 of 695) and the lowest in the West Midlands
(10%, 11 of 112) and Yorkshire & Humber (10%, 24 of
242) regions (figure 2).  In Wales and Northern Ireland
the prevalences were 10% (10 of 97) and 7% (11 of
153) respectively.
58. The UAPMP enhancement pilot found a comparable
prevalence (allowing for differences in test sensitivity
and recruitment areas) among IDUs in England outside
London in 2003/04 of 32% (305 of 943). 
Those participants in UAPMP enhancement pilot survey
who reported injecting crack-cocaine had a higher
prevalence than those who did not (44% (167 of 377)
and 24% (138 of 566) respectively).
59. Prevalence of anti-HBc among those who began
injecting in the previous three years is an indicator of
relatively recent transmission of hepatitis B virus.  
The UAPMP agency survey found that prevalence
among this group increased from 3.4% in 1997 to 9.1%
in 2003, and in 2004 it was 6.7% (23 of 345) (figure 3).
Hepatitis B
§§ Publication of hepatitis B surveillance data has stopped until the current problems with the routine 
laboratory surveillance system, some of which are currently being addressed, have been resolved.  
Whilst the quality of the data has been maintained in parts of the system publishing partial figures 
could give the false impression that cases of acute hepatitis B in England and Wales had fallen. 16 Shooting Up 
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Hepatitis A
60. Up to the end of the 1990s, hepatitis A infection in the
UK occurred most frequently in gay men and travellers
to endemic countries. There is an effective vaccine that
is offered to those at risk9. There appears to have been a
change in the epidemiology of hepatitis A in the early
part of the decade with significant numbers of infections
occurring in IDUs who may have acquired hepatitis A
infection through person-to-person contact with other
infected individuals through poor hygiene, via blood
through sharing contaminated injected equipment,
through sexual activities that increase risk of oro-faecal
contamination, or from drugs that have been
contaminated with faeces during smuggling.  
61. In 2004 the number of laboratory reports of hepatitis A
in England and Wales was 627 compared with 984 in
2003 and 1,352 in 200251. Only a small, and declining,
proportion of hepatitis A reports contained information
on risk factors and in 2004 only 7% (44 of 627) had
such information. Travel abroad was the most frequently
mentioned risk factor (73%, 32 of 44) in 2004 as
opposed to injecting drug use being the most frequently
reported risk factor in 2003. In the early part of the
decade there had been a number of outbreaks of
hepatitis A that were associated with injecting drug use
and homelessness52. The 2004 data suggest that the
outbreaks of hepatitis A in IDUs have been waning.  
62. An outbreak of hepatitis A infection among IDUs in
Scotland occurred in Aberdeen during 2000 and 2001,
and involved 74 IDUs. A case-control study revealed that
poor hygiene, related to individuals preparing and
injecting drugs together, had provided an opportunity
for transmission53. During June to December 2003,
there was an increase in the number of notifications of
hepatitis A in Ayrshire, Scotland; 13 cases were reported
among IDUs54.
63. HTLV-II is endemic among native Amerindian tribes 55,
and in Europe it has been documented among IDUs 56.
HTLV-II infection has been associated with neurological
disorders57, an increase risk of bacterial infections, and in
those co-infected with HIV an increase risk of
neuropathy58.
64. During 2003 and 2004, 185 individuals were newly
diagnosed with HTLV and reported to CfI, of whom
seven were known to be HTLV-II-infected and one a
HTLV-I&II co-infection59. Of the eight individuals
diagnosed with HTLV-II infection the probable route of
infection was reported for five individuals: one was
infected through injecting drug use, two were infected
through heterosexual intercourse with an IDU partner,
one was infected through heterosexual intercourse with
no information on the partner, and one was infected
through transfused blood. Where reported (five), four
were born in the UK and one in Africa. Four individuals
were tested as blood donors. As there is no routine
testing for the infection among IDUs, HTLV-II infection
among this group is likely to be under-diagnosed.
HTLV-II (Human T-Cell Lymphotropic Virus, type II)
65. Transmission of HIV through injecting drug use was
recognised early in the HIV epidemic at the beginning
of the 1980s. Explosive outbreaks of HIV infection
among IDUs have occurred worldwide, with ongoing
transmission in Eastern Europe. Other than an outbreak
in Edinburgh in the early 1980’s HIV infection among
IDUs has remained relatively uncommon in the UK,
probably as a result of prompt community and public
health responses.  
66. By the end of 2004 there had been a total of 4,239 HIV
diagnoses reported in the UK where infection had
probably been acquired through injecting drug use.
These accounted for 6% of all the diagnoses reported
(70,808) in the UK, 4.5% (2,964 of 65,385) of the
reported infections in England, 30% (1,222 of 4,067) 
in Scotland, 4.5% (45 of 1003) in Wales and 2.3% 
(8 of 353) in Northern Ireland.
67. The annual number of HIV diagnoses among IDUs in
recent years has been low and constant (table 1), at an
annual average of 122 reports during the period 1998
to 2003. So far, 118 HIV diagnoses, where infection was
thought to have been acquired by injecting drug use,
have been reported in the UK for 2004 (50 in London,
11 in Scotland, and 57 elsewhere). Of these diagnoses,
country of infection was reported for 73 (62%).
Where reported, 32 (44%) infections were probably
acquired within the UK and 41 (56%) outside of the UK,
mostly in Southern Europe. Where country of birth was
reported (63), 38% (24) were born within the UK and
62% (39) outside of the UK, mostly in Southern Europe. 
68. Among 218 IDUs attending GUM clinics in Scotland
during 2004, one HIV infection was detected, yielding a
prevalence of 0.5%. This finding is consistent with rates
observed in recent years; prevalences ranged from 2.5%
to 5.3% during the early to mid-1990s and from 0% to
1.5% during 1998 to 2003. The surveillance of persons
undergoing voluntary confidential HIV testing in
Scotland found a prevalence of 0.5% among 2,115 IDUs
during 2004; this rate compares with prevalences of
1.4% to 3.2% in the early to mid-1990s and 0.5% to
0.8% during the period 1998 to 2003 (table 1).
69. The UAPMP agency survey found a HIV prevalence of
3.9% (25 of 645) among IDUs in London in 2004 and a
prevalence of 0.6% (11 of 1,940) elsewhere in England
and Wales. This is the highest HIV prevalence seen
outside London in this survey since 1993. The UAPMP
enhancement pilot found a prevalence of 0.7% (7 of
952) among IDUs in England outside London in
2003/04. The prevalence of HIV infection among IDUs
attending services taking part in the UAPMP agency
survey in Northern Ireland was 2.0% (3 of 153,
combining data for 2003 and 2004).
70. A recent analysis combining data from IDUs
participating in the UAPMP agency survey with data
from IDUs recruited through a series of community
recruited surveys undertaken by CRDHB has permitted a
closer examination of trends in HIV infection among
current IDUs in England and Wales between 1990 and
200360. HIV prevalence was found to have declined in
the early 1990s from 5.6% in 1990 to 0.6% in 1996 and
then to have increased in the most recent years to 1.4%
in 2003. The prevalence amongst current IDUs
participating in the UAPMP agency survey in England in
Wales in 2004 was 1.5% (24 of 1,574), this is the
highest level seen amongst current IDUs in this survey
since 1992 when the prevalence was 2.0% (40 of
2,005) (figure 1). In London the prevalence 
among current IDUs in 2004 was 4.4% (16 of 361) 
and elsewhere in England and Wales it was 0.7% 
(8 of 1,213).
71. In 2004, 37% of IDUs (944 of 2,550) who took part in
the UAPMP agency survey reported never having had a
voluntary confidential test for HIV. Of those who had
antibodies to HIV, only 50% (15 of 30) were aware of
their infection, this is the lowest level of awareness 
seen in this survey since this was first asked about in
1995 (the average between 1995 and 2003 was 74%
(172 of 232)).
72. The community recruited cohort study of recently
initiated IDUs undertaken by CRDHB in London
estimated that HIV incidence to be 3.4% per annum 46.
As this incidence is similar to the prevalence in London
at that time it is suggestive of a recent increase in
transmission. Corroboration for this comes from UAPMP
agency survey, in which since 2003 the HIV prevalence
among those who had begun injecting in the
proceeding three years was higher than that found in
earlier years: in 2004 it was 0.6% (2 of 345) (figure 3).
73. The cohort study also found evidence that the
incidence of HIV among those who reported injecting
crack-cocaine during follow-up was around 6%, which is
higher than among those who had not injected crack-
cocaine. Whilst the UAPMP enhancement pilot found
that those who reported injecting crack-cocaine had a
higher prevalence than those who did not (1.3% (5 of
382) and 0.4% (2 of 570) respectively).
HIV
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74. The recent, and probably ongoing, increase in the
prevalence of HIV infection among current IDUs is a
cause for concern. Whilst HIV infection still remains
comparatively rare among this group overall, with
around one in 65 infected, it is elevated among IDUs in
London with around one in 25 infected. Although many
of the new diagnoses of HIV infection associated with
injecting drug use are attributed to infection acquired
aboard there is evidence of ongoing transmission within
the UK and that this has most probably increased in
recent years.
75. The prevalence of hepatitis C infection has also
increased with more than two in five current IDUs now
having been infected. This, and the incidence studies,
indicates that transmission of hepatitis C among IDUs
may have increased since the beginning of the current
decade. Further insights into the extent of current
transmission will come from the ongoing incidence
study in Wales.
76. The higher levels of HIV and hepatitis C infections
among those who report using crack-cocaine are of
particular concern. These associations with crack-
cocaine use need further investigation in order to
inform effective prevention, for example, whether it is
the prevention of crack-cocaine injection or addressing
other factors associated with crack-cocaine use, such as
homelessness, that is important. Nevertheless, the high
levels are worrying as whilst injecting crack-cocaine,
usually in combination with opiates would currently
appear to be focused in some areas of the UK, there is
evidence to suggest that both the use and injection of
crack-cocaine are becoming more common61.
77. The proportion of IDUs in contact with drug services
reporting having had a voluntary confidential test for
hepatitis C has increased. However, half of IDUs with
hepatitis C infection in contact with drug services in
England and Wales are still unaware of their infection. 
It is likely that a higher proportion of those with
hepatitis C who are not in contact with drug services
will be unaware of their infection. More worryingly half
of IDUs in contact with drug services were unaware of
their HIV infection in 2004, twice the level seen in 
earlier years.  
78. More than one in five injectors have been infected with
hepatitis B, and new infections are continuing to occur.
Vaccine coverage continues to increase with the
majority of IDUs now having taken up the offer of
vaccination. This improvement in uptake probably
reflects improved provision through drug services and,
in particular, the prison vaccination programmes. 
In England around two-fifths of prisons offer a hepatitis
B vaccination, and now that Primary Care Trust are
responsible for delivering prison health services uptake
should continue to rise. Since the Scottish Prison Service
introduced its hepatitis B vaccination programme to all
inmates in 1999, there have been no outbreaks of acute
hepatitis B infection among IDUs in Scotland 21. It is of
concern that few IDUs in the UAPMP enhancement
survey reported having received vaccination doses
through NEX, given that these are likely to be the first
drug service that new IDUs will come into contact with.  
79. Hepatitis A vaccination is very effectively preventing
infection among IDUs9,62. Where appropriate,
consideration should be given to introducing hepatitis A
vaccination in conjunction with existing hepatitis B
vaccination programmes. A combined hepatitis A and B
vaccine is available and this may be more popular with
clients than offering the single vaccines together 62.
80. The reasons for the continuing occurrence of MRSA and
elevated level of severe GAS infections are unclear and
need further investigation, though they may possibly
reflect an increased vulnerability of IDUs to skin sepsis
through a change in risk behaviour63. This might be
associated with the increased use of stimulants, such as
crack-cocaine61, which UAPMP enhancement found to
be associated with both risk behaviours and symptoms
of injecting site infections. This survey also indicated
that overall symptoms of injecting site infections were
common among IDUs.
81. The continuing occurrence of wound botulism cases
indicates an ongoing problem with environment
contamination of heroin with bacterial spores. A similar
increase in wound botulism amongst IDUs occurred in
California in the mid-1990s 64, and the use of ‘black tar’
heroin (which differs to that generally used in the UK)
was identified as a contributing factor 64. The increase in
reports in the UK may reflect better case recognition
and monitoring, although this is unlikely to fully explain
the increase seen. The clustering of wound botulism
cases in 2004, and an absence of cases in some areas
with higher levels of drug injecting (such as Merseyside),
supports the possibility of a causal relationship between
the cases, possibly the contamination of specific heroin
batches. Since a major risk factor is also skin- or muscle-
‘popping’38,35,41, injection practices are also likely to be
important, and variations in these might explain the
absence of outbreaks in other European countries.
However, small numbers of cases have been reported in
several countries65,66,67,68. Healthcare workers should
remain alert to the possibility of clostridial infections
among IDUs, particularly those who inject
subcutaneously or intramuscularly.
82. Considering the recent outbreak of tetanus, health
professionals in contact with IDUs should ask about their
tetanus immunisation status. IDUs who have not
received five doses of tetanus-containing vaccine or are
unsure about their vaccination status, should be offered
additional vaccination boosters as appropriate.
Unvaccinated IDUs should be encouraged to complete 
a full course of vaccinations9.
Comments and Conclusions
83. In the late 1990s the reported levels of needle and
syringe (direct) sharing during the previous month
increased63, and this higher level of sharing has been
sustained since then. Data from across the UK suggest
that almost one in three IDUs reported direct sharing
during the previous month in 2004. Data from the
UAPMP enhancement survey also suggest extensive
reuse of needles and syringes.  
84. Concern has been raised about the coverage of NEX
services and that this may have been insufficient 13.
Moreover, there is also evidence of a shift away from
agency-based provision towards pharmacy-based
services69. Whereas agency-based NEX typically provide
a range of other services, such as face-to-face advice
and vaccination, this is not usually the case with
pharmacy-based services. Studies have suggested that
IDUs using pharmacy-based NEX rather than agency
based ones may be more likely to share70. The current
lack of a UK wide NEX monitoring system means that it
is not possible to assess changes in provision. However,
national audits of NEX are underway in England,
Scotland and Wales and these will shortly provide
important information on current provision. 
85. The significant reductions in both frequency of injecting
and rates of direct sharing among recent initiates in
Glasgow22 following the introduction of the new
guidelines by Scotland's Lord Advocate, allowing greater
numbers of needles and syringes to be obtained per
NEX visit, are encouraging. While these changes may
have stemmed from factors other than the increased
availability of needles and syringes, the study
investigators22 concluded that “it would seem prudent
to continue with the current new policy on needle and
syringe distribution” and that further work should be
undertaken to encourage IDUs to make use of their
entitlement to a greater number of sterile needles 
and syringes.  
86. Improvements are needed to IDUs injection hygiene so
as to reduce the growing burden from injecting related
infections. Infections, such as hepatitis C, may be
reduced by the provision of sterile injecting equipment
other than needles and syringes. NEX services should,
when appropriate, offer clients ampoules of sterile water
for injection, swabs, utensils for preparation (such as
spoons), citric acid, and filters in addition to needles 
and syringes. Those commissioning services should
monitor NEX provision to ensure adequate coverage 
so as to provide sufficient needles and syringes to
prevent sharing and that provision is responsive to
changing patterns of drug use and risk. They should 
also consider what other injecting related items should
be provided locally. 
87. The national drugs strategy2,19 has since the late 1990s
broadened the focus of policy around drug use from a
public health perspective to the minimisation of the
wider social harms, including crime and anti-social
behaviour71. This has resulted in a welcome expansion
of treatment services with the aim of getting more
users off drugs.  It also identifies the need for further
action to “improve the health of drug misusers and
drive forward action to reduce the risk of death”.
Considering the current extent of injecting related
infections, services should be commissioned to provide
clear information and advice on safer injecting, injecting
related infections, and the importance of safe disposal
of injecting equipment; on-site access to vaccination
and voluntary confidential testing services; basic health
checks for injection site infections; and easy referral to
treatment services for those who wish to modify and
reduce their drug use.  
88. There is also a need for research projects to develop,
pilot and evaluate innovative intervention options for
improving injection hygiene, such as novel approaches
to providing practical training to IDUs on safer injecting.
Such projects should draw upon the lessons learnt in
other countries such as the pilots of safer injection
facilities72,73,74. There would also appear to be a need for
research to explore the role of both crack-cocaine use
and injecting, and appropriate service responses.
89. IDUs in the UK are continuing to contract a wide range
of infections, and public health surveillance systems
need to be maintained and developed to provide
continued vigilance. In particular there is a need to
improve surveillance of viral hepatitis through the more
consistent reporting by laboratories of diagnoses with
complete risk factor information. Systems to improve
our understanding of the extent of injecting site
infections need to be investigated and developed.
90. The UAPMP agency survey continues to provide valuable
data on blood-borne viruses and associated risks among
IDUs in contact with services. The UAPMP enhancement
pilot has provided important additional data, particularly
on behaviours and drug use, and its continuation needs
to be considered. Particularly as the development and
pilot of a companion unlinked anonymous survey in
Scotland could in the future provide comprehensive 
UK-wide data.  
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Notifiable diseases
Tetanus. Laboratories are requested to report all confirmed cases to Cfi in England, to the NPHSW in Wales, to CDSC in
Northern Ireland and to HPS in Scotland. Information and advice for clinicians, microbiologists and injecting drug users in
England and Wales is available on the HPA website at: http://www.hpa.org.uk/infections/topics_az/tetanus/menu.htm and
from HPS for Scotland at http://www.show.scot.nhs.uk/scieh/infectious/tetanus/tetanus.html
In formation on reference laboratory services for tetanus are included in the RSIL User manual at 
http://www.hpa.org.uk/srmd/div_rsil/rsiluser.pdf
Hepatitis A. Laboratories are requested to report all confirmed cases to CfI in England, to the NPHSW in Wales, to CDSC in
Northern Ireland and to HPS in Scotland. Information and advice for clinicians and injecting drug users in England and Wales
is available on the HPA website at:  http://www.hpa.org.uk/infections/topics_az/hepatitis_a/menu.htm
Hepatitis B & C. Laboratories are requested to report all confirmed cases to CfI in England, to the NPHSW in Wales, to CDSC
in Northern Ireland and to HPS in Scotland.  
Further information can be found for hepatitis B at http://www.hpa.org.uk/infections/topics_az/hepatitis_b/menu.htm and
http://www.show.scot.nhs.uk/scieh/infectious/hepatitisb/infhepatitisb.htm
Further information can be found for hepatitis C at http://www.hpa.org.uk/infections/topics_az/hepatitis_c/menu.htm and
http://www.show.scot.nhs.uk/scieh/infectious/hepatitisc/infhepatitisc.html
Support for management of individual cases and their contacts and of outbreaks is available at local level from the Health
Protection Unit and at national level from the CfI and National Public Health Service for Wales (Wales), CDSC Northern Ireland
and HPS (Scotland).  Policy advice on vaccination (tetanus, hepatitis A & B) is developed for the UK by the UK Joint
Committee on Vaccination and Immunisation.  Policy advice for viral hepatitis is developed for the UK by the Department of
Health Advisory Group on Hepatitis.
Other infections
Wound botulism. Information and advice for clinicians and injecting drug users in England and Wales is available on the
HPA website at: http://www.hpa.org.uk/infections/topics_az/botulism/menu.htm
Laboratory investigation of cases of botulism (detection of neurotoxin and isolation of Clostridium botulinum): Food Safety
Microbiology Laboratory, CfI, HPA, 61 Colindale Ave, London NW9 5EQ. Telephone: 020 8200 4400
Other clostridia infections. Identification of other clostridial, or other anaerobic, isolates from IDU wounds, blood and
cultures: Anaerobe Reference Laboratory, NPHS Microbiology Cardiff, University Hospital of Wales, Cardiff, CF14 4XW Tel
02920 742378 or 742171
Group A streptococci. Information and advice for clinicians in England and Wales is available on the HPA website at:
http://www.hpa.org.uk/infections/topics_az/strepto/pyogenic/menu_a.htm
In formation on reference laboratory services for GAS are included in the RSIL User manual at 
http://www.hpa.org.uk/srmd/div_rsil/rsiluser.pdf
Staphylococcus aureus infections. Information and advice for clinicians is available on the HPA website at:
http://www.hpa.org.uk/infections/topics_az/staphylo/menu.htm. Identification and characterisation of MSSA and MRSA from
IDUs: Staphylococcus Reference Laboratory, CfI, HPA, 61 Colindale Avenue, London, NW9 5EQ. Telephone: 020 8327 7227.
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Reports of HIV infection
Voluntary confidential reports of new HIV diagnoses in adults
(15+ years) are received from laboratories and clinicians in
England, Wales, Northern Ireland and Scotland. Reports are
collated on a quarterly basis to form a UK dataset.
Surveillance began in 1982 with AIDS case reporting, and
expanded to include laboratory reporting of HIV diagnoses in
1985. In England, Wales, and Northern Ireland, clinician HIV
reports were introduced in 2000 to supplement laboratory
reporting, and the AIDS report was phased out. AIDS
information is now collected on the clinician HIV report.  
Laboratory reports of viral hepatitis & bacterial
infection
Clinically significant infections diagnosed in England, Wales
and Northern Ireland are routinely reported to CfI and held
on a central system known as LabBase2. Most laboratories
participate in the system, but reporting is not mandatory.
LabBase2 is therefore one of the most comprehensive
sources of surveillance data, covering nearly all
microbiologically-confirmed infections. Data on MRSA, group
A streptococci and hepatitis A, B and C were all extracted
from this reporting system. These reports contain
demographic and risk information, with the risk factor
information not always being provided. In Scotland, HPS
collates data on all confirmed HCV antibody tests from the
main HCV testing laboratories in Glasgow, Edinburgh,
Dundee and Aberdeen.  
The Unlinked Anonymous Prevalence Monitoring
Programme’s Survey of Injecting Drug Users
The UAPMP aims to measure the distribution of infection in
sub-groups of the adult population. In the surveys that make
up the UAPMP, samples are irreversibly unlinked from any
identifying information before testing. The UAPMP’s surveys
have ethical approval. 
The UAPMP survey of IDUs monitors HIV, hepatitis B and
hepatitis C in those injectors in contact with specialist
services, such as needle exchanges, or on treatment
programmes, such as methadone maintenance. Those who
agree to participate provide a saliva sample and complete a
behavioural questionnaire. Detailed methods used for the
survey have been published previously1. The survey of IDUs
has been ongoing since 1990 in England & Wales, and was
extended to Northern Ireland in 2002.
Further information about the UAPMP and comprehensive
tables of data are available at:
http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/hiv/e
pidemiology/ua.htm
A pilot of an enhancement to the UAPMP survey of IDUs
started in 2003. This collaboration between CRDHB and the
CfI uses fieldworkers to target recruitment in settings were the
UAPMP agency survey is difficult to deploy, such as mobile
needle exchanges and through community recruitment. 
This collects dried blood spot specimens rather than oral 
fluid samples.  
Reference laboratory submissions
The key source of data on MRSA in IDUs is through referral of
isolates to the SRL (part of CfI) for reference microbiology. 
Isolate referrals to the national reference laboratory RSIL (part
of CfI), are one of the primary sources of GAS infection reports
(see strep-EURO below).
Data on Clostridial infections are also available from reference
microbiology work. For botulism this is carried out by FSML,
and for tetanus by RSIL. For the other clostridia this
undertaken by the Anaerobe Reference Laboratory, NPHS
Microbiology Cardiff.
strep-EURO 
Data from reference laboratory isolates and   routine
laboratory reports have been combined as part of a two year
enhanced surveillance programme. Augmented surveillance
data was being sought through questionnaires sent to
microbiologists nationally.  
Notifications of infectious disease
Clinicians throughout the UK are required by law to report a
number of defined conditions to their local communicable
disease specialist. Tetanus and hepatitis A, B and C are among
these notifiable diseases.
Enhanced surveillance of tetanus 
Enhanced surveillance of tetanus is carried out by the CfI
Immunisation Department
http://www.hpa.org.uk/infections/topics_az/tetanus/menu.htm
Surveillance of wound botulism 
Surveillance of wound botulism among IDUs is carried out by
the CfI HIV & STI Department, with FSML. Reports are followed
up with a surveillance questionnaire.
HTLV
The HIV & STI Department at CfI collates reports of new HTLV
diagnoses in England and Wales from laboratories 
and clinicians.
Data sources
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